Ronald C. Renaud, Jr. Intends Not to Stand for Re-Election to Chimerix, Inc.'s Board of Directors
April 10, 2020 at 07:31 pm
Share
On April 6, 2020, Ronald C. Renaud, Jr. notified Chimerix, Inc. that he did not intend to stand for re-election to the Company’s Board of Directors upon the expiration of his term as a Class I director at the Company’s 2020 Annual Meeting of Stockholders. Mr. Renaud’s decision was driven by the need to devote additional time to his role as Chief Executive Officer and a director of Translate Bio, Inc. and other professional obligations, and was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
Chimerix, Inc. is a biotechnology company. The Company is focused on developing medicines that address unmet medical needs. The Company's product Imipridones is a cancer therapy that provides ONC201, which is in clinical-stage development for H3 K27M-mutant glioma as its lead indication. In addition, imipridone ONC206 is in dose-escalating clinical trials. Imipridones target specific G protein-coupled receptors (GPCRs) and mitochondrial caseinolytic protease P (ClpP), resulting in cancer cell death. The Company's product Imipridone chemical scaffold provides an opportunity to target GPCRs and ClpP with tunable specificity and modality, which enables therapeutic use for cancer and other diseases. Its ONC206 is an imipridone, Dopamine Receptor D2 (DRD2) antagonist and ClpP agonist. Its ONC212 is an imipridone, an investigational agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP. Its CMX521 is a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2.
CHIMERIX, INC. 
